Nanyang Biologics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Reverse Merger
  • (Announced)

  • Latest Deal Amount
  • $1.5B

  • Investors
  • 2

Nanyang Biologics General Information

Description

NYB Holdings Ltd, along with its subsidiaries, is a pre-clinical biopharmaceutical company engaged in the research and development of therapeutics and nutraceuticals derived from biodiversity, including tropical medicinal plants with a history of traditional use. It focuses on discovering and developing natural compounds for applications in oncology and other chronic diseases, and also offers a consumer nutraceutical product line.

Contact Information

Website
nyb.group
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • Nanyang Avenue
  • Singapore
  • Singapore
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Nanyang Avenue
  • Singapore
  • Singapore

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nanyang Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Reverse Merger 02-Oct-2025 $1.5B Announced Generating Revenue
2. Accelerator/Incubator 03-Mar-2025 Completed Clinical Trials - Phase 1
1. University Spin-Out 01-Jan-2020 Completed Startup
To view Nanyang Biologics’s complete valuation and funding history, request access »

Nanyang Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nanyang Biologics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
The Ignition AI Accelerator Accelerator/Incubator
Nanyang Technological University University
To view Nanyang Biologics’s complete investors history, request access »

Nanyang Biologics Acquisitions (1)

Nanyang Biologics’s most recent deal was a Merger/Acquisition with RF Acquisition II. The deal was made on 02-Oct-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
RF Acquisition II 02-Oct-2025 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Nanyang Biologics’s complete acquisitions history, request access »

Nanyang Biologics FAQs

  • When was Nanyang Biologics founded?

    Nanyang Biologics was founded in 2020.

  • Where is Nanyang Biologics headquartered?

    Nanyang Biologics is headquartered in Singapore, Singapore.

  • What is the size of Nanyang Biologics?

    Nanyang Biologics has 16 total employees.

  • What industry is Nanyang Biologics in?

    Nanyang Biologics’s primary industry is Drug Discovery.

  • Is Nanyang Biologics a private or public company?

    Nanyang Biologics is a Private company.

  • What is the current valuation of Nanyang Biologics?

    The current valuation of Nanyang Biologics is .

  • What is Nanyang Biologics’s current revenue?

    The current revenue for Nanyang Biologics is .

  • Who are Nanyang Biologics’s investors?

    The Ignition AI Accelerator and Nanyang Technological University have invested in Nanyang Biologics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process